A possible explanation for the additive effect of the combination of SZU-106 conjugation and DAC treatment is that in addition to activate TLR7 signaling pathways in immune cells, conjugated SZU-106 can also facilitate to initiate tumor antigen specific antigen presentation by bringing more tumor specific antigen to DC cells through binding to the TLR7 molecules on the surface of DC cells. Here, TLR7 is linked to neoplasm.